ReviewThe Journal of infectious diseases2017
Mycoplasma genitalium Infection in Men.
Review in The Journal of infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 137 citations in OpenAlex.
- Genital mycoplasma infection: a systematic review and meta-analysis.Reproductive health · 2023Pooled it
- Drug resistance ofFrontiers in cellular and infection microbiology · 2026Review
- Towards precision management ofFrontiers in cellular and infection microbiology · 2026Article
- Interactions of Mycoplasma genitalium (Mg) and human papillomavirus (HPV) infections among couples.BMC infectious diseases · 2025Article
- In vitro evolution provides insights into mechanisms of Mycoplasma genitalium resistance to moxifloxacin.The Journal of antimicrobial chemotherapy · 2025Article
- Development and clinical evaluation of a novel SHERLOCK test forMicrobiology spectrum · 2025Article
- Infections of chlamydia trachomatis, mycoplasma genitalium and neisseria gonorrhoeae among the outpatients of reproductive medicine center in Chongqing, China: a retrospective study.BMC infectious diseases · 2025Article
- Clinical characteristics and symptoms associated withSexually transmitted infections · 2025Article
- Factors that contribute to the success of primary isolation ofJournal of medical microbiology · 2025Article
- A novel azithromycin resistance mutation in Mycoplasma genitalium induced in vitro.The Journal of antimicrobial chemotherapy · 2025Article
- Prevalence ofSexually transmitted infections · 2024Article
- Prevalence ofOpen forum infectious diseases · 2024Article
- Cost-effectiveness of resistance-guided therapy for Mycoplasma genitalium in Australia.Scientific reports · 2024Article
- Identification of phytochemical inhibitors targeting phosphate acetyltransferase of Mycoplasma genitalium: insights from virtual screening and molecular dynamics studies.Molecular diversity · 2024Article
- Computational approach for identifying immunogenic epitopes and optimizing peptide vaccine throughHeliyon · 2024Article
- Effectiveness of sitafloxacin monotherapy for quinolone-resistant rectal and urogenital Mycoplasma genitalium infections: a prospective cohort study.The Journal of antimicrobial chemotherapy · 2023Article
- Viruses, bacteria and parasites: infection of the male genital tract and fertility.Basic and clinical andrology · 2023Review
- gyrA Mutations in Mycoplasma genitalium and Their Contribution to Moxifloxacin Failure: Time for the Next Generation of Resistance-Guided Therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Article
- Mycoplasma infection mimicking a malignancy in a waldenstrom macroglobulinemia patient.BMC infectious diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Mycoplasmagenitalium is one of the major causes of nongonococcal urethritis (NGU) worldwide but an uncommon sexually transmitted infection (STI) in the general population. The risk of sexual transmission is probably lower than for Chlamydia trachomatis. Infection in men is usually asymptomatic and it is likely that most men resolve infection without developing disease. The incubation period for NGU caused by Mycoplasma genitalium is probably longer than for NGU caused by C. trachomatis. The clinical characteristics of symptomatic NGU have not been shown to identify the pathogen specific etiology. Effective treatment of men and their sexual partner(s) is complicated as macrolide antimicrobial resistance is now common in many countries, conceivably due to the widespread use of azithromycin 1 g to treat STIs and the limited availability of diagnostic tests for M. genitalium. Improved outcomes in men with NGU and better antimicrobial stewardship are likely to arise from the introduction of diagnostic M. genitalium nucleic acid amplification testing including antimicrobial resistance testing in men with symptoms of NGU as well as in their current sexual partner(s). The cost effectiveness of these approaches needs further evaluation. The evidence that M. genitalium causes epididymo-orchitis, proctitis, and reactive arthritis and facilitates human immunodeficiency virus transmission in men is weak, although biologically plausible. In the absence of randomized controlled trials demonstrating cost effectiveness, screening of asymptomatic men cannot be recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.